The somatic mutations in a cancer genome are the aggregate outcome of one or more mutational processes operative through the lifetime of the individual with cancer 1-3 . Each mutational process leaves a characteristic mutational signature determined by the mechanisms of DNA damage and repair that constitute it. A role was recently proposed for the APOBEC family of cytidine deaminases in generating particular genomewide mutational signatures 1,4 and a signature of localized hypermutation called kataegis 1, 4 . A germline copy number polymorphism involving APOBEC3A and APOBEC3B, which effectively deletes APOBEC3B 5 , has been associated with modestly increased risk of breast cancer 6-8 . Here we show that breast cancers in carriers of the deletion show more mutations of the putative APOBEC-dependent genome-wide signatures than cancers in non-carriers. The results suggest that the APOBEC3A-APOBEC3B germline deletion allele confers cancer susceptibility through increased activity of APOBECdependent mutational processes, although the mechanism by which this increase in activity occurs remains unknown.
The somatic mutations in a cancer genome are the aggregate outcome of one or more mutational processes operative through the lifetime of the individual with cancer [1] [2] [3] . Each mutational process leaves a characteristic mutational signature determined by the mechanisms of DNA damage and repair that constitute it. A role was recently proposed for the APOBEC family of cytidine deaminases in generating particular genomewide mutational signatures 1,4 and a signature of localized hypermutation called kataegis 1, 4 . A germline copy number polymorphism involving APOBEC3A and APOBEC3B, which effectively deletes APOBEC3B 5 , has been associated with modestly increased risk of breast cancer [6] [7] [8] . Here we show that breast cancers in carriers of the deletion show more mutations of the putative APOBEC-dependent genome-wide signatures than cancers in non-carriers. The results suggest that the APOBEC3A-APOBEC3B germline deletion allele confers cancer susceptibility through increased activity of APOBECdependent mutational processes, although the mechanism by which this increase in activity occurs remains unknown.
In recent analyses of somatic mutational signatures in 21 primary human breast cancers that underwent whole-genome sequencing 1 , 2 signatures characterized by C>T and/or C>G mutations at TCX trinucleotides were identified (where the underlined base is the mutated base and X can be any base). These signatures were subsequently observed in several other cancer types ( Fig. 1a and Online Methods) and are among the most common mutational signatures found in human cancer ( Supplementary Fig. 1a,b) 1, 9 . These signatures have been designated signatures 2 and 13 (according to the nomenclature of Alexandrov et al. 9 ). Signature 2 is composed predominantly of C>T transitions with fewer C>G transversions in a TCX sequence context. In contrast, signature 13 is dominated by C>G transversions in a TCX context 1, 9 . A subset of breast cancers and other cancer types have an extremely large number of mutations of these signatures, and we have called these cancers 'hypermutators ' (refs. 1,9) .
The features of the mutations associated with signatures 2 and 13 resemble those of mutations generated by the AID/APOBEC family of cytidine deaminases 10, 11 . Members of this gene family have important physiological roles in antibody diversification (AICDA) and the restriction of retroviruses and mobile retroelements (for example, APOBEC3A and APOBEC3G) (reviewed in refs. [11] [12] [13] . However, it has been suggested that the DNA editing capabilities of these enzymes could also underlie undesirable mutagenesis leading to cancer 4, 11, 14, 15 . Indeed, in addition to AICDA, a capacity for the editing of nuclear DNA has been demonstrated for APOBEC3A 14, 16, 17 , APOBEC1, APOBEC3C and APOBEC3G 10 .
A common germline copy number deletion polymorphism involving the APOBEC3 gene cluster on chromosome 22 (Fig. 1b) has been associated with elevated risk of breast cancer. A genome-wide association study (GWAS) of copy number in 16,000 cases of 8 common diseases highlighted this deletion polymorphism in association with breast cancer in a primary screen, although the association was not validated in replication 6 . Subsequently, a GWAS in the Chinese population demonstrated an association of the deletion polymorphism with breast cancer (odds ratio (OR) = 1.3 for one-copy deletion and 1.8 for two-copy deletion; P = 2.0 × 10 −24 ) 7 that was replicated in a European population (OR = 1.2 for one-copy deletion and 2.3 for two-copy deletion; P trend = 0.005) 8 . The deletion allele has a frequency of ~8% in European populations 5, 6 , 37% in East Asians and 93% in Oceanians 5 . The ~29,500-bp genomic deletion has delimiting breakpoints in APOBEC3A and APOBEC3B (which are adjacent to each other and in the same orientation on chromosome 22) and results in a chimeric APOBEC3A-APOBEC3B gene. This hybrid gene is predicted to produce a transcript that is predominantly constituted of APOBEC3A sequence but replaces the APOBEC3A 3′ UTR with the APOBEC3B 3′ UTR (Supplementary Note) and encodes a protein Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer l e t t e r s that has an identical amino acid sequence to that of APOBEC3A 5 (Fig. 1b) . Homozygous carriers of this deletion allele are predicted not to make any APOBEC3B protein. Given the association of the deletion allele with breast cancer, we explored the relationship between this allele (Table 1 ) and the presence of mutational signatures 2 and 13.
We aggregated a set of 923 breast cancers from multiple sequencing centers in which normal and neoplastic tissues had been sequenced for somatic mutations-123 by whole-genome sequencing and 800 by whole-exome sequencing (Supplementary Table 1a,b) . Using next-generation sequence data, we identified 128 cases that were heterozygous and 14 that were homozygous for the APOBEC3A-APOBEC3B deletion allele (Online Methods, Supplementary  Fig. 2a-c 
, Supplementary Table 2a-c and Supplementary Note).
Applying the non-negative matrix factorization (NNMF) algorithm, employed to extract mutational signatures 1, 9, 18 , to the somatic mutations, we estimated the number and proportional contribution of mutations attributable to each mutational signature in each cancer case ( Supplementary Fig. 1c-o and Supplementary Table 1b) . Combining these two sets of results, we observed that cancers with a higher mutational burden of signatures 2 and 13 were more likely to be derived from individuals who were carriers of at least one copy of the germline APOBEC3A-APOBEC3B deletion allele (Wilcoxon ranksum test P = 1.7 × 10 −3 ; Online Methods, Supplementary Fig. 3b ,e, and Supplementary Note). In particular, the subset of hypermutator cancers 19 (Supplementary Table 3a ) was associated with the deletion allele. Breast cancers from individuals who were heterozygous or homozygous for the APOBEC3A-APOBEC3B deletion allele had a relative risk of 2.37 (confidence interval (CI) = 1.64-3.46) of being hypermutators compared to breast cancers from individuals who did not carry the deletion allele (Cochran-Armitage P = 6.251 × 10 −6 ; Table 1 ). In contrast, no association was found between the deletion allele and signature 1, another mutational signature common in breast and other cancers (P = 0.935). The results therefore suggest that the APOBEC3A-APOBEC3B deletion allele is specifically associated with the burden of signature 2 and 13 mutations in breast cancer (see Table 1 , Supplementary Table 3b and the Supplementary Note for discussion of population stratification).
We then examined 1,769 cancers of 11 other cancer types in which signature 2 and 13 mutations have been found ( Table 2 and Supplementary Fig. 3b-d) 11 . Of 40 individuals with acute lymphoblastic leukemia (ALL), 3 were hypermutators ( Table 2) ; all 3 were carriers of the germline deletion allele, with 2 heterozygous and 1 homozygous for the allele (P = 2.51 × 10 −5 ). Enrichment for hypermutators among cases who were heterozygous and homozygous for the deletion allele was also seen in bladder carcinoma, although this enrichment did not reach statistical significance (P = 0.038, Bonferroni-corrected P = 0.452; Table 2 ). Thus, the APOBEC3A-APOBEC3B deletion allele may be associated with the signature 2 and 13 mutational burden in cancers other than breast cancer.
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In the cohort of 923 breast cancers, the majority of cases had a mutation rate of signatures 2 and 13 of less than 1 mutation per megabase. A subset of cases had mutations comprising mostly (or, in some cases, entirely) signatures 2 and 13 with a very high mutation rate associated with these signatures (hypermutators). A higher proportion of cases were found to be carriers of at least one copy of the germline deletion allele among cases with hypermutator breast cancers. A test for trend demonstrates a correlation between the number of copies of the deletion allele in a breast cancer case and having a hypermutator breast cancer (P = 6.251 × 10 −5 ).
npg l e t t e r s cancers ( Supplementary Fig. 3c ,d) suggests that multiple factors are likely to influence the burden of signature 2 and 13 mutagenesis, such as inherited variation in the APOBEC genes, APOBEC gene expression, virus or transposon activity, and inflammation, and that these factors may vary in importance in different cancers. If signatures 2 and 13 are due to APOBEC activity, they should bear the known characteristics of the mutations generated by these enzymes. The substitution classes in signatures 2 and 13 (C>T transitions and C>G transversions, respectively) coupled with the TC sequence context of the mutations were responsible for the initial proposition of the role of the APOBEC enzyme family in generating these signatures 1 . However, APOBEC-induced mutations exhibit other distinctive characteristics, including preferential cytosineto-uracil deamination on stretches of single-stranded DNA [20] [21] [22] . Consequently, adjacent APOBEC-induced mutations often arise on the same parental allele (in cis with each other) and are on the same DNA strand (where successive mutations may be C>T… C>G… C>T or G>A… G>C… G>A but not C>T… G>A… C>T), a pattern referred to as strand-coordinated mutagenesis (Online Methods and Supplementary Note).
To investigate the presence of strand-coordinated mutagenesis in signatures 2 and 13 ( Supplementary Fig. 4a-c) , we examined the frequencies of 2 successive mutations arising on the same strand and on different strands in the 123 breast cancers that had undergone whole-genome sequencing. Several cancers had more strand-coordinated pairs of mutations than expected by chance (corrected for the mutation spectrum and mutation burden; Fig. 2a) , and this level of strand-coordinated mutagenesis was directly correlated with the proportion of signature 2 and 13 mutations in these cancers (r = 0.74; P = 1.1 × 10 −21 ; Fig. 2b) . Furthermore, examination of next-generation sequencing reads in these cancers showed that strand-coordinated mutations usually occurred in cis (P < 0.0001; Supplementary Fig. 4d, Supplementary Table 4 and Supplementary Note), confirming that these mutations are linked to each other on the same parental haplotype. Taken together, these findings are compatible with the model in which signature 2 and 13 mutations often arise on stretches of single-stranded DNA, similar to the mutations induced by APOBEC enzymes 4, 20 .
The association between the germline APOBEC3A-APOBEC3B deletion allele and signature 2 and 13 mutational burden (OR = 2.68 for one-copy deletion and 3.82 for two-copy deletion, P trend = 6.251 × 10 −6 ; combined OR = 2.78, CI = 1.75-4.41) is in keeping with the reported modest increase in risk of breast cancer conferred by the deletion allele based on GWAS. However, the mechanism by which the germline APOBEC3A-APOBEC3B fusion confers elevated APOBEC mutagenic activity is unclear. The amino acid sequence of the predicted fusion protein is identical to that of APOBEC3A, although the transcript is a chimera of APOBEC3A and a segment of the 3 UTR of APOBEC3B, which could confer altered transcriptional or translational regulation of APOBEC3A. The other consequence of the APOBEC3A-APOBEC3B germline deletion allele is deletion of the APOBEC3B coding sequence and, thus, absence of APOBEC3B protein in homozygous carriers of the deletion allele (Supplementary Fig. 5a ). It is not immediately clear, however, how this deletion of APOBEC3B would directly increase APOBECrelated mutagenesis.
The TC sequence context of the mutations generated by APOBEC1 (refs. 23,24), APOBEC3A 22 and APOBEC3B 22, 25, 26 closely mirrors the sequence context of signature 2 and 13 mutations in human cancers, indicating that these particular members of the APOBEC enzyme family are likely candidates for generating these mutational signatures 4, 22 . Thus far, there have been no recurrent somatic mutations identified in the APOBEC gene family that can be associated with signature 2 or 13. On the basis of gene expression studies, recent reports have suggested that APOBEC3B is responsible for the occurrence of these signatures in cancers [27] [28] [29] . However, the existence of signature 2 and 13 hypermutator breast cancers in individuals with germline homozygosity for the APOBEC3A-APOBEC3B deletion allele, which completely removes APOBEC3B coding sequences (Fig. 1b) , and in whom APOBEC3B expression is absent (Online Methods, Supplementary Fig. 5a ,b and Supplementary Note) 30 indicates that elevated activity of APOBEC3B is unlikely to be exclusively responsible for signature 2 and 13 mutations.
The burden of somatic mutations due to signatures 2 and 13 is one of the highest attributable to any mutational signature across the spectrum of human cancer 11 . Thus, elucidation of the mechanisms underlying signature 2 and 13 mutations will advance understanding of carcinogenesis in several cancer types and may potentially influence strategies for cancer prevention and treatment. The effect of the APOBEC3A-APOBEC3B germline deletion allele on the signature 2 and 13 mutational burden reported here provides independent evidence for the underlying role of members of the APOBEC gene family npg l e t t e r s in generating these mutations. Furthermore, it provides a plausible biological mechanism by which this breast cancer predisposition allele could confer its effect. The geographic variation in the population frequency of the APOBEC3A-APOBEC3B germline deletion allele 5 suggests that there may be selection in favor of it (Online Methods).
As some APOBEC enzymes are involved in innate immunity 4, 11 to infection, it may be that protection against infection is conferred by the deletion allele. This protection may be counterbalanced, to some extent, by predisposition to cancer. If true, this would be remarkable, as both effects would be mediated by the same underlying mechanism-the double-edged sword of the mutagenic activity of the APOBEC proteins.
URLs. CGhub, https://cghub.ucsc.edu/; TCGA data hub, https:// browser.cghub.ucsc.edu/; HGDP Selection Browser, http://hgdp. uchicago.edu/.
METHODs
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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npg ONLINE METHODs
Background information. Cancer samples for next-generation sequencing (whole genome and whole exome) were previously sequenced by members of the International Cancer Genome Consortium (ICGC), The Cancer Genome Atlas (TCGA) and other centers 9, 18 . High-confidence somatic substitutions were obtained from these consortia or other peer-reviewed publications not related to these consortia, filtered further for potential false positive calls using dbSNP, the 1000 Genomes Project database, the National Heart, Lung, and Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project and the 69 Complete Genomics panel as well as a bespoke panel of BAM files of unmatched normal tissues containing more than 120 normal genomes and 500 exomes 9 . These data were then parsed through an algorithm previously developed to extract mutational signatures in human cancers 18 called NNMF 9, 18 . Six main substitution classes (C>A:G>T, C>G:G>C, C>T:G>A, T >A:A>T, T>C:A>G and T>G:A>C) were subdivided according to 5′ and 3′ flanking sequence context. As there were 6 classes of base substitution and 16 possible sequence contexts for each mutated base (A, C, G or T at the 5′ base and A, C, G or T at the 3′ base), there were 96 possible mutated trinucleotides for each cancer. Herein, the convention for describing a mutated trinucleotide was XCX, where X can be any base and the mutated base is underlined 1, 2, 9, 18 .
A total of 7,042 samples were analyzed from 30 types of cancer, and 21 distinct mutational signatures were extracted. The most common signatures were signatures 1A and 1B, both characterized by C>T mutations in an XCG trinucleotide context (Supplementary Fig. 1a) , and signatures 2 and 13, characterized by dominant C>T transitions in a TCX sequence context in signature 2 and C>G transversions in a TCX sequence context in signature 13 ( Supplementary Fig. 1a,b) 1, 2, 9, 18 . Signature 1A and 1B mutations are likely to be caused by deamination at methylated CpGs, whereas signature 2 and 13 mutations are thought to be due to the activity of the APOBEC family of cytidine deaminases. Therefore, for the purpose of this analysis, signatures 2 and 13 were considered together. NNMF is able to estimate the number of mutations associated with extracted mutation signatures for individual cancers in a given set of samples (summarized in Supplementary Fig. 1c-o and  Supplementary Table 1b) .
In this analysis, a total of 2,719 samples were previously characterized by NNMF and also had BAM files available for inspection (Supplementary  Table 1a,b) . BAM files were downloaded from CGhub between 9 May 2013 and 26 June 2013. For ease in tracking samples throughout this analysis, we have kept the naming convention attached to the cancer sample for tables and figures, even if the germline deletion polymorphism was sourced from a matched normal sample, as the signatures of somatic mutagenesis would have been identified in the tumor samples in the first place. This notation was also kept for the purpose of continuity between publications. For samples originating from the Sanger Institute, PDXXXX denotes a specific individual, with an 'a' , 'c' or 'd' suffix denoting tumor samples and a 'b' suffix indicating the matched normal sample.
Detection of the germline APOBEC3A-APOBEC3B deletion polymorphism. To detect the deletion polymorphism from next-generation sequencing data, multiple loci within and flanking the coordinates of the deletion were sampled (Supplementary Fig. 2a and Supplementary Table 2a ) from BAM files (the overall workflow and directions for processing data are provided in Supplementary Fig. 2b ). Raw short read data had been aligned back to the reference genome (NCBI Build 37), with duplicates and unmapped reads removed. Externally sourced BAM files were obtained from the TCGA data hub.
BAM files for matched normal samples were sought for calling this deletion allele. However, a BAM file for a tumor was used if one for a normal sample was not available (Supplementary Table 2b) . Samples that did not have BAM files available for examination were excluded from analysis. In total, detection of the APOBEC3A-APOBEC3B polymorphism was sourced from 561 tumors (99 BLCA, 117 BRCA, 1 CESC, 19 HNSC, 2 KIRP, 303 LUAD, 12 STAD, 2 THCA and 6 UCEC) and 2,158 normal samples.
For samples with whole-genome data, the expected sequencing depth in the absence of the deletion polymorphism-that is, wild-type copy number of 2 or d 2 -was calculated as the average sequencing depth of the 60 loci in the flanking regions. The expected sequencing depth in the presence of a heterozygous deletion allele, d 1 , was given by d 1 = d 2 /2, and the expected depth in the presence of a homozygous deletion allele, d 0 , was set to the expected number of misreads, estimated as d 2 /20. A maximum-likelihood test was performed to identify the most likely copy number from the set 31 , with corresponding expected sequencing depths represented as Poisson distributions (Pois(d 0 ), Pois(d 1 ) and Pois(d 2 )), given the observed sequencing depths within the region of the deletion polymorphism (Supplementary Data Set 1) .
For exome-sequenced samples, an expectation maximization algorithm was used, with the copy number of each sample and the ratio of the sequencing depths within and outside the deletion polymorphism region used as latent variables. The copy number of each sample was initialized as 2, and the depth ratio of loci within the deletion polymorphism region relative to loci outside, r, was modeled non-parametrically by bootstrap resampling (n = 1,000). For samples with copy number of 2, 1 and 0, respectively, the expected sequencing depths within the deletion polymorphism region were given by At each maximization step, the copy number of each sample was assigned as the one that had the distribution showing the most overlap with d inside for that sample, after bootstrap resampling. At each expectation step, r was recalculated using bootstrap resampling of loci within just those samples classified as having copy number = 2 in the previous maximization step. The expectation maximization algorithm was continued until no samples were reclassified from one iteration to the next or for a maximum of 100 iterations ( Supplementary  Fig. 2b and Supplementary Data Set 2).
Results for the calling of polymorphism status in all samples are provided in Supplementary Table 2b . The reproducibility of the calling method was evaluated by examining the concordance between calling on the tumor and normal BAM files from the same individual (Supplementary Fig. 2c, Supplementary  Table 2c and Supplementary Note) as well as the concordance between genome-and exome-sequenced samples from the same individual.
Relationship between the APOBEC3A-APOBEC3B germline deletion allele and somatic mutational signatures in cancer. The data set comprised genome-sequenced (123) as well as exome-sequenced (800) cancers. To perform the analyses, the rate of mutation was calculated for each cancer (rate of signature 2 and 13 mutations per megabase of DNA), correcting for whether the samples had been sequenced over the genome or exome.
Because the rates of signature 2 and 13 mutations were not normally distributed ( Supplementary Fig. 3a-d) , a one-sided Wilcoxon rank-sum test was performed to determine whether carrying one copy of the deletion allele had an overall effect on the mutation rate of the signatures.
We sought to include more cancer samples to increase the power of the analyses. There were no further available breast cancer samples with BAM files ready for download; hence, we sought inclusion of other cancer types that had previously been analyzed 9, 18 . However, it was noted that distributions of the rates of signature 2 and 13 mutations varied considerably among cancer types (Supplementary Fig. 3b-d) , and clear outliers were present in all the cancer types, skewing the distributions of mutation rate ( Supplementary  Fig. 3a,d,e) .
Some cancers were observed to have a strikingly high proportion of total mutations associated with signatures 2 and 13 and/or to have higher rates of mutagenesis associated with these signatures (Supplementary Figs. 1c-o and  5c) . Using the rate of signature 2 and 13 mutagenesis, outliers were identified as cases with cancers that had a mutation rate exceeding 1.5 times the length of the interquartile range from the 75th percentile for each type of cancer 19 . We refer to these outliers as hypermutators, although we do not suggest that there is an ongoing biological process attached to this name. Given the considerable variation in the mutation rates for different cancer tissue types (Supplementary Fig. 1a,b) , each cancer type was analyzed separately. A summary of the hypermutators versus non-hypermutators is provided in Supplementary Table 3a. npg Strand-coordinated mutagenesis. In theory, neighboring mutations could arise on either of two strands of a double helix (Supplementary Fig. 4a ), particularly if they had arisen as independent events during different cycles of cell division. If more mutations are observed to occur on the same strand than expected by chance (Supplementary Fig. 4b ), this would imply one of two scenarios: either the neighboring mutations arose over different rounds of cell division with preferential targeting of one strand over another or they arose during a single round of cell division and potentially occurred in the same instance.
We sought to formally document that neighboring mutations are occurring on the same strand more often than expected by chance in strand-coordinated mutagenesis. To demonstrate genome-wide strand coordination, analysis was carried out on all whole-genome sequence data for which BAM files were available (Supplementary Table 4) . Given a set of mutations, each occurring at a base of type A, C, G or T on the plus strand, we identified all pairs of mutations and classified them as 'same' if both mutations were of the same originating base and 'diff ' if not (first and second mutations of each pair, respectively: A>X and A>X; G>X and G>X; C>X and C>X; and T>X and T>X, with no previous selection for mutations in a TC context). The distance between successive pairs or intermutation distance was also calculated (Supplementary Fig. 4c) .
The proportion of the pairs of mutations that were expected to occur on the same base assuming randomly ordered mutations was given by p p p p
+ + + , where p X is the fraction of mutations that occurred at nucleotide X. To depict the deviation of the observed pairs of mutations found on the same strand from that of the expected pairs of mutations on the same strand, a standard Forest plot was constructed (data for expected and observed same-strand mutations for all 124 samples are provided in Supplementary  Table 4 , columns b-e).
Because same-strand mutations were ascertained in an unbiased way from any mutation type (not restricted to just cytosine mutations at TC sites), to determine whether strand-coordinated mutations were a particular feature of signatures 2 and 13, we sought a relationship between the degree of strand coordination, given by the OR of strand coordination, and the fractional burden of signature 2 and 13 mutations in each cancer (Supplementary Fig. 4d) .
We sought additional characteristics of the mutations in the breast cancers that underwent whole-genome sequencing that supported the suggestion that mutations associated with signatures 2 and 13 had arisen owing to the activity of the APOBEC family of enzymes (Supplementary Fig. 4d, Supplementary  Table 4 and Supplementary Note).
Relationship between expression of APOBEC family members and the rates of mutation for signatures 2 and 13. RNA sequencing-derived expression data were obtained from the UCSC Genome Browser for relevant samples. In total, there were 1,691 cases for which comparable data were obtainable. Expression levels for each APOBEC family member were standardized relative to the levels of TBP (encoding TATA-binding protein), and the relationship between APOBEC3B expression levels and germline deletion allele status in these cancers was evaluated (Supplementary Fig. 5a,b and Supplementary Table 5 ).
Selection for the APOBEC3A-APOBEC3B deletion. The germline APOBEC3A-APOBEC3B deletion polymorphism highlighted in this analysis was reported to display a strikingly differentiated worldwide distribution of allele frequencies 5 . The F ST value (measuring population differentiation) was reexamined using reported deletion allele frequencies and additional SNP genotype data from the Human Genome Diversity Cell Line Panel (CEPH-HGDP) panel published after the CNP study 32 . This value depends on the way populations are grouped and needs to be compared with the values for other variants of similar frequency to measure how unusual it is. We used 2 published grouping schemes, involving division into 5 continental geographic/genetic groups ((i) sub-Saharan Africans, (ii) Middle Easterners plus Europeans, (iii) East Asians, (iv) Native Americans and (v) Oceanians) or into 32 population groups 33 , and matched SNP frequencies measured as minor allele frequency to ±0.1%. For the five continental groups, F ST was 0.330 (97.4 percentile compared with 2,716 frequency-matched SNPs), and for the 32 population groups it was 0.285 (96.6 percentile compared to 2,059 frequency-matched SNPs). The level of population differentiation was thus higher than expected by chance, which can result from positive selection 34 , and we therefore examined other statistics sensitive to positive selection. Cross-population extended haplotype homozygosity (XP-EHH) and integrated haplotype score (iHS) values were obtained from the HGDP Selection Browser. These haplotype-based tests for positive selection 35 use information for sequences 500 kb upstream and downstream of the deletion, and the two flanking regions can thus be examined separately. Neither flanking region showed a significantly high XP-EHH (>2.5) or iHS (|iHS| > 2.0) value in any continental group or individual population. Finally, we looked at allele frequency spectrum-based tests (Tajima's D, Fay and Wu's H and the composite likelihood ratio test from Nielsen et al. 36 ) using 1000 Genomes Project Phase 1 resequenced data in the East Asian populations (CHB, CHS and JPT) (1000G Phase 1) 37 in the regions surrounding the deletion, as described (1000G Pilot) 31 . There was no evidence for positive selection in these populations, although, in this case, the power of the tests was limited because the frequency of the deletion in these populations was not high enough.
Overall, this locus showed unusually high differentiation among continents and populations. However, there remained a lack of other evidence for positive selection, and we therefore cannot convincingly conclude that this deletion has been positively selected in human populations.
